EZH2 and skin squamous cell carcinoma: In cSCC, Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit (EZH2) (involved in histone methylation) seems to play a role in inhibiting the antitumoral immune response of the host, and it can be used in the future as an important target of specific antitumoral therapy [62].